MNMD Mind Medicine
- 8.4500
- -0.8100-8.75%
- 8.4700
- +0.0200+0.24%
Mind Medicine News
Mind Medicine Price Target Cut to $20.00/Share From $29.00 by Oppenheimer
Mind Medicine Price Target Cut to $20.00/Share From $29.00 by Oppenheimer
Oppenheimer Reiterates Outperform on Mind Medicine, Lowers Price Target to $20
Oppenheimer analyst Francois Brisebois reiterates Mind Medicine (NASDAQ:MNMD) with a Outperform and lowers the price target from $29 to $20.
Seritage Growth Properties Posts Q1 Loss, Joins Fortrea Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Monday.Shares of Seritage Growth Properties (NYSE:SRG) fell sharply in today's pre-market trading after
Mind Medicine Is Maintained at Buy by HC Wainwright & Co.
Mind Medicine Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : Maintaining the Mind Medicine (MNMD.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $75.00 to $35.00.
HC Wainwright & Co. : Maintaining the Mind Medicine (MNMD.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $75.00 to $35.00.
HC Wainwright & Co. Maintains Buy on Mind Medicine, Lowers Price Target to $35
HC Wainwright & Co. analyst Patrick Trucchio maintains Mind Medicine (NASDAQ:MNMD) with a Buy and lowers the price target from $75 to $35.
Mind Medicine Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 280.43% HC Wainwright & Co. $75 → $35 Maintains Buy 04/15/2024 117.39% Leerink Partners → $20 I
Mind Medicine (MindMed) Inc. (MNMD) Q1 2024 Earnings Call Transcript Summary
The following is a summary of the Mind Medicine (MindMed) Inc. (MNMD) Q1 2024 Earnings Call Transcript:Financial Performance:Mind Medicine raised approximately $175 million from an oversubscribed unde
Mind Medicine Presents New Studies At ISPOR 2024 Showing Growing Burden And Impact Of Generalized Anxiety Disorder In The U.S.
-GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life--People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed
Mind Medicine Inc (MNMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic Advances Amid ...
Mind Medicine Retained Executive Search Firm to Assist in Identifying a New CFO
Mind Medicine Retained Executive Search Firm to Assist in Identifying a New CFO
Mind Medicine Made Transition in CFO Role Resulting in Departure of Schond Greenway >MNMD
Mind Medicine Made Transition in CFO Role Resulting in Departure of Schond Greenway >MNMD
10-Q: Quarterly report
Mind Medicine Q1 2024 GAAP EPS $(1.14) Misses $(0.53) Estimate
Mind Medicine (NASDAQ:MNMD) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(0.53) by 115.09 percent. This is a 75.38 percent decrease over losses of $(0
Mind Medicine MindMed 1Q Loss/Shr $1.14 >MNMD
Mind Medicine MindMed 1Q Loss/Shr $1.14 >MNMD
"FDA Expert Committee Will Review MDMA-Assisted Therapy For PTSD Next Month" - Marijuana Moment
The Food and Drug Administration (FDA) is taking the next step in its historic review of MDMA-assisted therapy for the treatment of post-traumatic stress disorder (PTSD), scheduling a meeting next mon
MindMed Releases Promising Phase 2 Data on LSD-related Anxiety Therapy
Reported Saturday, MindMed Unveils Phase 2b Data Of MM120 For Generalized Anxiety Disorder At American Psychiatric Association Annual Meeting
-A single oral administration of MM120 100 μg met its primary and key secondary endpoints and maintained clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
-A single oral administration of MM120 100 μg met its primary and key secondary endpoints and maintained clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical
Press Release: MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update NEW YORK--(BUSINESS WIRE)--May 02, 2024-- Mind Medicine (MindMed) Inc. (NASDAQ
Analysis
Price Target
No Data
